US FDA Grants Investigational Device Exemption (IDE) to EndoQuest™ Robotics for Its Flexible Robotic System (GlobeNewswire)

EndoQuest Robotics, a leader in flexible endoluminal robotic technologies, has received FDA Investigational Device Exemption (IDE) approval for its pivotal PARADIGM clinical study. The trial will assess the safety and performance of the company’s innovative Endoluminal Surgical (ELS) System in robotic endoscopic submucosal dissection (ESD) procedures for colorectal lesion removal. Conducted across five top US healthcare institutions, including Brigham and Women’s Hospital and Mayo Clinic, the study aims to redefine minimally invasive colorectal procedures.